Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: AgAuUSA who wrote (8257)	2/26/1998 8:42:00 AM
From: Yo Yo	Read Replies (1) \| Respond to of 14328

Another False Alarm On the bright side.... Population of Malaysia is 20 million+ -------------------------------------------------------- Trinity Biotech Distributor Wins Government HIV Screening Tender in Malaysia BusinessWire, Thursday, February 26, 1998 at 08:23 DUBLIN, Ireland--(BW HealthWire)--February 26, 1998--TRINITY BIOTECH PLC (NASDAQ:TRIBY) is pleased to announce the successful acquisition of a Malaysian government tender by BIO-LINK Sendirian Berhad for the Uni-Gold(tm) HIV rapid test. The Uni-Gold(tm) HIV rapid test will be utilized in a government HIV screening program throughout Malaysia. Following local trials and evaluations, the Uni-Gold(tm) HIV product was chosen above competitive products for this program. The simplicity of this test, which uses whole blood as a sample, was a critical factor in meeting the government's requirements and needs. Ronan O'Caoimh, CEO of Trinity Biotech, commented, "The Uni-Gold(tm) HIV test is ideally suited to rapid, near patient testing -- without the use of instrumentation or complex laboratory procedures -- as it utilizes whole blood in a simple one-step procedure to give results in less than 10 minutes. We are pleased to see continuing expansion of our global distribution of this successful product." Trinity Biotech develops, manufactures and markets diagnostic products that address all three segments of the diagnostic market: (1) rapid tests for the emerging point-of-care (POC) market, (2) simplified tests for the self-test (OTC) market, and (3) microtitre plate kits for the clinical laboratory market. The company's products are sold in over 65 countries around the world. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the Company's Securities and Exchange Commission filings. CONTACT: TRINITY BIOTECH PLC Jonathan O'Connell Chief Financial Officer (800) 603-8076